In this video, Maria Caterina Rotiroti, PhD, discusses notable presentations on chimeric antigen receptor T-cell therapy at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
“As a PhD working on CAR T-cell immunotherapy, I was particularly interested in the preclinical sessions focused on next-generation CAR designs,” Rotiroti, a postdoctoral fellow at Dana-Farber Cancer Institute, told Healio.
She also highlighted presentations investigating mechanisms of resistance following CAR T-cell therapy.

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.
Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend survival, reduce recurrence and mitigate chemotherapy-related toxicity. The benefits appeared consistent across a variety of disease subtypes.
However, investigators acknowledged the results must be interpreted with caution.
The findings came from retrospective cohort studies, so prospective validation will be essential. The possibility that GLP-1s may exacerbate endocrine therapy side effects, as well as

A bacteria found in the gut may “very important” to the development of lupus and lupus nephritis, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
“We have evolved to interact with our microbes,” said Gregg Silverman, MD, of the New York University Grossman School of Medicine.
When those interactions go awry, the consequences can lead to more than just infection, he added.
“Maybe your immune system can wander,” Silverman said. “If there is an imbalance, bad things may happen.”
Silverman described data